Adalimumab Improves IBD Outcomes

Higher levels of adalimumab (ADL) are associated with improved disease outcomes and remission in patients with inflammatory bowel disease (IBD), according to a recent study.

Little information is available on the relationship between pharmacokinetic features of ADL and disease outcome in IBD patients.
_____________________________________________________________________________________________

RELATED CONTENT
Anti-TNF Therapy May Increase Risk for IBD
Why Do Some IBD Patients Have Poor Response to Treatment?
_____________________________________________________________________________________________

In their study, the researchers examined 157 serum samples from 87 patients with IBD who received long-term maintenance therapy with ADL. Patients included in the study had either Crohn disease or ulcerative colitis. Follow-up lasted 6 months.

Results indicated that serum ADL levels were associated with clinical remission. Patients with a normal C-reactive protein value demonstrated serum ADL levels of 9.2 μg/mL, while patients with a high C-reactive protein value demonstrated levels of 5.2 μg/mL.

The researchers found that ADL levels were also significantly associated with normal fecal calprotectin value and to successful deintensification with a cutoff value of 12.2 μg/mL, compared with patients whose treatment dosage was unchanged.

“Higher ADL levels were significantly associated with clinical and biochemical remission,” the researchers concluded. “Our results, which were obtained under conditions of daily clinical practice, suggest that an ADL cutoff of 12.2 μg/mL could be appropriate for successful dose reduction in patients with IBD treated with ADL.”

—Christina Vogt

Reference:

Aguas Peris M, Bosó V, Navarro B, et al. Serum adalimumab levels predict successful remission and safe deintensification in inflammatory bowel disease patients in clinical practice [Published online July 12, 2017]. Inflamm Bowel Dis. doi:10.1097/MIB.0000000000001182.